Arming of iPSC-Derived NK Cells Expressing a Novel CD64 Fusion Receptor with Therapeutic Antibodies Represents a Novel Off-the-Shelf, Antigen-Targeting Strategy for Cancer
Kate Dixon(University of Minnesota), Bruce Walcheck(University of Veterinary Science), Ryan Bjordahl(Fate Therapeutics (United States)), Jeffrey S. Miller(Science Museum of Minnesota), Soheila Shirinbak(Fate Therapeutics (United States)), Jianming Wu(Guangxi Academy of Agricultural Science), Paul Rogers(Fate Therapeutics (United States)), Zachary Davis(University of Minnesota), Bahram Valamehr(Fate Therapeutics (United States)), Melissa Khaw(University of Minnesota), Martin Hosking(Fate Therapeutics (United States)), Kristin M. Snyder(University of Minnesota), Robert Hullsiek(University of Minnesota), Tom Lee(Fate Therapeutics (United States)), Hui-Yi Chu(Fate Therapeutics (United States))
Cited by 0
Related Papers
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
|Blood|2013|537
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
|Blood|2018|406
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
|Clinical Cancer Research|2018|195